Nanogen Enters Into Supply and License Agreement With deCode Genetics

Apr 18, 2005, 01:00 ET from Nanogen, Inc.

    SAN DIEGO, April 18 /PRNewswire-FirstCall/ -- Nanogen, Inc.
 (Nasdaq:   NGEN), developer of advanced diagnostic products, announced today
 that it has entered into a supply and license agreement with deCode Genetics
 to provide a new genomics assay for single nucleotide polymorphism (SNP)
 discovery, validation and screening.  The assay incorporates a full range of
 Nanogen's products, including the Eclipse(R) Dark Quencher, new DNA linker
 technology, modified bases and novel fluorescent dyes, and allows rapid SNP
 analysis on a large number of patient samples.
     "The products and assay that we will provide deCode represent our
 comprehensive product menu available from the recent merger of Nanogen and
 Epoch Biosciences," said Howard C. Birndorf, Nanogen's chairman of the board
 and CEO.  "We are pleased deCode has joined our roster of licensing partners
 eager to tap our growing portfolio of products that enable rapid,
 high-throughput genetic analysis."
     About Nanogen, Inc.
     Nanogen's advanced diagnostics provide physicians and patients worldwide
 with sophisticated information to predict, diagnose and treat disease.
 Research and clinical reference labs use the highly accurate and reliable
 NanoChip(R) Molecular Biology Workstation, NanoChip(R) Electronic Microarray
 and broad suite of analyte specific reagents to develop diagnostic tests for
 variety of diseases.  Nanogen also offers a broad portfolio of patented
 nucleic acids chemistries and molecular tools that accelerate genomic analysis
 and are compatible with many systems.  The SynX subsidiary offers a line of
 point-of-care diagnostic tests and is building expertise in cardiac related
 health conditions.  Nanogen's ten years of pioneering research involving
 nanotechnology may also have future applications in medical diagnostics,
 biowarfare and other industries.  For additional information please visit
 Nanogen's website at
     Forward-Looking Statement
     This press release contains forward-looking statements that are subject to
 risks and uncertainties that could cause actual results to differ materially
 from those set forth in the forward-looking statements, including whether
 patents owned or licensed by Nanogen will be developed into products, whether
 the patents owned by Nanogen offer any protection against competitors with
 competing technologies, whether products under development can be successfully
 developed and commercialized, whether results reported by our customers or
 partners can be identically replicated, and other risks and uncertainties
 discussed under the caption "Factors That May Affect Results" and elsewhere in
 Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and
 Exchange Commission.  These forward-looking statements speak only as of the
 date hereof.  Nanogen disclaims any intent or obligation to update these
 forward-looking statements.

SOURCE Nanogen, Inc.